Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Deferred Revenue: 2024

Historic Current Deferred Revenue for Prime Medicine (PRME) over the last 1 years, with Dec 2024 value amounting to $7.1 million.

  • Prime Medicine's Current Deferred Revenue fell 25.10% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 25.10%. This contributed to the annual value of $7.1 million for FY2024, which is N/A change from last year.
  • Prime Medicine's Current Deferred Revenue amounted to $7.1 million in FY2024.
  • Prime Medicine's 5-year Current Deferred Revenue high stood at $7.1 million for FY2024, and its period low was $7.1 million during FY2024.
  • Over the past 1 years, Prime Medicine's median Current Deferred Revenue value was $7.1 million (recorded in 2024), while the average stood at $7.1 million.